About Dapagliflozin (Amorphous) API
Therapeutic CategoryAnti-Diabetic
CAS Number
461432-26-8
API Technology
Synthetic
Dose Form
Oral Solids
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Canada DMF, Korea DMF, Russia DMF
Mechanism of Action
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion
Indication
FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Related APIs
Dapagliflozin (Amorphous)
Anti-Diabetic
Dapagliflozin (PG Solvate Monohydrate)
Anti-Diabetic
Glimepiride
Anti-Diabetic
Linagliptin
Anti-Diabetic
Liraglutide
Anti-Diabetic
Pioglitazone Hydrochloride
Anti-Diabetic
Sitagliptin Hydrochloride
Anti-Diabetic
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!